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Abstract
Background: Recently, equine multipotent mesenchymal stromal cells (MSC) have received significant attention as
therapy for various conditions due to their proposed regenerative and immune-modulating capacity. MSC are
commonly administered to the patient through a hypodermic needle. Currently, little information is available on
the effect of such injection has on equine MSC immediate and delayed viability. We hypothesize that viability of
equine MSC is not correlated with needle diameter during aspiration and injection.
Results: Using a 3 mL syringe, manual injection of equine cord blood (CB) or bone marrow-derived (BM) MSC
with no needle and needles ranging in size from 18 to 30 Ga did not affect immediate MSC viability. Similarly, 24 h
post-injection, MSC delayed viability was not different between any of the tested needles as determined by a
resazurin-based proliferation assay. Using a 3 mL syringe, aspiration of MSC through 20, 25, and 30 Ga needles
resulted in significant decreases in immediate viability with no change in delayed viability when compared to
aspiration without a needle. BM- and CB-MSC were observed to be of similar size with a diameter ± SD of 19.8 ± 2.7 and
20.4 ± 2.2 μm, respectively. In comparison, the smallest needles, (30 Ga) have an internal diameter of 160 μm.
Conclusions: Following injection, needle diameter did not affect immediate or delayed viability of equine MSC.
Following aspiration through needles sizes 20 Ga and smaller, immediate viability, but not delayed viability,
decreased. As a result, an 18 Ga or larger needle should be utilized for aspiration of cell suspensions. In contrast, needle
selection for MSC injection should be based on clinical preference and experience rather than concerns over decreasing
MSC viability.
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Background
Multipotent mesenchymal stromal cells (MSC)—commonly
referred to as mesenchymal stem cells—are thought to have
potential as a therapeutic option for orthopedic injuries. In
human and veterinary medicine, promising results have
been reported in vivo following treatment of joint injuries,
cartilage defects, and tendon injuries using MSC therapy
[1–6]. The current practice of MSC therapy requires ad-
ministration of a cell-based suspension into the target tissue
or structure by injection through a hypodermic needle. In
order for stem cells to retain their potential benefits,
immediate and delayed viability must not be significantly
affected by cell collection, culture, preparation, or injection.
The FDA has recommended greater than 70 % viability for
cell based therapeutic product prior to injection [7]. Cur-
rently there is little reliable evidence as to the effect of as-
piration or injection of equine stem cell products through
hypodermic needles.
One of the defining characteristics of MSC is their ability
to adhere to tissue culture-treated polystyrene plastic. In
order for MSC to be used as a therapeutic agent, they must
be detached from the culture flask and suspended in liquid
prior to injection. This process results in spindle-shaped
adherent MSC transforming into spherical free-floating
MSC. Reported diameters for suspended rat- and human-
derived MSC range from 12–15 μm [8]. The diameter of
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equine MSC in suspension is not available in the scientific
literature. The effect of aspiration and injection on MSC
has not been investigated separately. However, intermittent
negative pressure was shown to decrease MSC viability in
one human wound-healing study [9]. Additionally, Sharp
and Mohammad [10] report human red blood cell damage
has been reported to increase following injection at pres-
sures greater than those clinically relevant. In this report,
injection of whole blood through large diameter needles in-
duced greater red blood cell damage than small diameter
needles when injection was performed at a constant pres-
sure [10]. This cellular trauma likely occurs as a result of
greater differences in velocity (and hence sheer stress) be-
tween fluid in the central (fast flowing) portion of the nee-
dle compared to fluid at the slow moving periphery that
occur in large diameter needles. Considering pressures well
beyond those experienced under clinical conditions were
utilized the relevance of this study [10] is unknown. De-
creased equine MSC viability has been reported following
repeated aspiration and injection of MSC suspensions [11]
indicating injection associated trauma can be induced
under certain conditions. An increase in apoptotic markers
following injection of equine MSC through small diameter
needles has been reported to possible sheer stress effects
[12]. However, it is undetermined at this point in time if
sheer stress affects equine MSC viability since the author’s
of the latter study appear to have misinterpreted the above
study by Sharp and Mohammad [10]. In the latter study
[12] they report that the Sharp and Mohammad study
showed increased sheer stress following injection through
small diameter needles, when in fact Sharp and Moham-
mad report increased sheer stress following injection
through large diameter needles.
While rat and human bone marrow- (BM-) derived
MSC viability did not appear related to needle size or in-
jection rate [8, 13], these findings may not be applicable
to equine MSC as numerous species-dependent factors,
most notably MSC size, are likely different. This being
said, the internal diameter of a 30 Ga hypodermic needle
is 160 μm, which is considerably larger than any cell.
We therefore hypothesize that viability of suspended
equine MSC following aspiration or manual injection is
not correlated with needle diameter. The aims of this
study were to evaluate MSC immediate and delayed via-
bility 24 h following separate aspiration and injection
through a variety of needle sizes commonly used in vet-
erinary medicine.
Methods
Preparation of cell suspensions
From nine unrelated horses, 5 BM- and 4 CB-MSC cul-
tures were selected from cryopreserved stock for use in
this study. Standard isolation protocols were used in the
collection, culture, and cryopreservation of all MSC
cultures as described elsewhere [14–16]. BM-MSC cul-
tures had been cryopreserved once and CB-MSC cul-
tures twice prior to commencement of this study. Each
cryovial containing 1×106 MSC was thawed in a 37 °C
water bath and transferred to either BM-MSC culture
media (DMEM low glucose, 10 % fetal bovine serum
(FBS), 1 % L-glutamine, and 2 % penicillin/streptomycin)
or CB-MSC culture media (containing 30 % FBS, other-
wise identical) and cultured at 38 °C, 5 % CO2, in a hu-
midified atmosphere to obtain necessary MSC numbers.
All MSC cultures were between passage 3–5 and 19–36
days in culture at the time of injection. MSC were
detached from culture flasks using trypsin-EDTA and
suspended in their respective culture media at a concen-
tration of 5×106 MSC/mL. MSC suspensions were stored
in polypropylene vials, at room temperature, in culture
media for the duration of the experiment. For injection
and aspiration studies MSC cultures were in suspension
at room temperature for 12 and 4 h respectively.
Effect of injection on MSC viability
Using a 3 mL Luer-lock syringe, 0.5 mL of the above cell
suspension was injected over a 2 s period into 1.5 mL
Eppendorf vials with the needle tip hovering at the top
of each vial. One individual (LW) performed injection
with the following needles attached to the syringe: no
needle, 18Ga x1.5”, 20Ga x1”, 22Ga x1”, 23Ga x3/4”,
25Ga x5/8”, 27Ga x1/2”, and 30Ga x1”. Duplicate injec-
tions were performed for each cell population and nee-
dle combination. Cell viability was determined using an
automated fluorescence-based cell counter (Nucleocoun-
ter NC-100, Mandel Scientific Company, Guelph, ON).
Each injected cell suspension was seeded into two wells
of a 96 well plate at a density of 5000/cm2 and cultured
for 24 h in 300 μL of respective culture media. Subse-
quently, a resazurin assay, which had been previously
optimized according to the manufacturer’s instructions,
was used to assess delayed viability by replacing cell
culture media with 300 μL of 10 % resazurin (Sigma-
Aldrich, Oakville ON) in phosphate buffered saline.
The cells were incubated 4 h before fluorescence was
read using an automated plate reader (Spectramax i3,
Molecular Devices, Sunnyvale CA) at 585 nm using an
excitation wavelength of 555 nm.
Effect of aspiration on MSC viability
Three BM- and three CB-MSC cultures were selected
from the above cell cultures to evaluate the effect of as-
piration on MSC viability. MSC suspensions were pre-
pared as described above with the following exception:
0.5 mL of MSC in suspension were slowly aspirated
using a 3 mL syringe by one operator (LW) through the
following: no needle, 20x1”, 25x5/8”, 30x1” needles, at a
rate of 0.25 mL/s. Needles were removed prior to
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ejection of cell suspensions from the syringe. Immediate
and delayed viability were assessed as described above
using duplicate samples for each cell suspension/needle
combination. Fewer needles were selected for these as-
piration studies since no differences were expected based
on the injection experiments. In addition, needle size
used for aspiration is less critical since the needle used
for aspiration is commonly replaced prior to injection.
Measurement of cell diameter in suspension
The diameter of suspended BM- and CB-MSC was mea-
sured by capturing digital images of cell suspension
using a digital inverted microscope (EVOS FL, Life
Technologies, Carlsbad CA) and measuring cell diam-
eter using software (Image J 1.48, National institutes of
health, Bethesda MD, USA) calibrated to the scale bar
associated with each image. The diameter of 100 cells
was recorded for BM- and CB-MSC cultures with mean
and standard deviation (SD) reported.
Statistical analysis
Viability and fluorescence data was imported into a stat-
istical analysis software package (SAS 9.2, SAS institute,
Cary, NC). A general linear model was used to analyze
the effect of MSC source (either BM or CB) and needle
size using the PROC MIXED function. Residual analysis
was performed in order to determine if ANOVA as-
sumptions were met, to detect potential outliers, and
evaluate the need for data transformation. Immediate
viability (expressed as percentages) for both aspiration
and injection portions of the study were analysed follow-
ing a logit transform with bias correction as follows:
logit = log[(r + k)/(n–r + k)] where r viable cells, out of n
total cells, and k is the bias correction term, 0.25). De-
layed viability for aspiration and injection portions of
the study were analysed following a natural log
transform.
The residuals were formally tested for normality
using the four tests offered by SAS (Shapiro-Wilk,
Kolmogorov-Smirnov, Cramer-von Mises, Anderson-
Darling) and plotted against the predicted values and
variables used in the model. Cell diameters were com-
pared using a two sample t-test (R 3.0.1, R foundation
for statistical computing, Vienna, Austria). For the
purpose of determining statistical significance, α was
set at 0.05.
Results
Effect of injection on MSC viability
Regardless of the tissue source or needle size, >89 % im-
mediate viability was achieved. Immediate viability was
significantly increased in MSC injected through 25 Ga
needles (p = 0.01), Fig. 1a. There was no difference be-
tween cells originating from BM or CB, and no inter-
action was detected between MSC source and needle
gauge. There were no differences in fluorescence from
MSC cultures assessed using the resazurin assay regard-
less of cell source or needle gauge, and no interaction
was detected between MSC source and needle gauge,
Fig. 1b.
Effect of aspiration on MSC viability
Following aspiration, needle size had a significant effect
on MSC immediate viability (p < 0.0001), but not on de-
layed viability, Fig. 2. Compared to non-aspirated con-
trols, 20, 25, and 30 Ga needles all decreased MSC
viability (p = 0.04, 0.0003, and <0.0001, respectively).
There was no difference in MSC immediate or delayed
viability between MSC from BM and CB origins, and no
interaction was detected between MSC source and nee-
dle gauge.
Fig. 1 Viability following injection of equine mesenchymal stromal cells; (a) Immediate and (b) delayed viability of MSC following injection
through various needle diameters as assessed using a propidium iodide based automated cell counter and resazurin fluorometric assay,
respectively. Differences in viability between MSC tissue sources were not detected, as a result data was combined for analysis. Error bars
represent 95 % confidence interval. Asterisks* (*p < 0.05) indicate significant difference from non-injected samples
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Measurement of cell diameter in suspension
No difference was detected between BM- and CB-MSC
diameters (p = 0.12). Mean ± SD diameters of 19.8 ±
2.7 μm and 20.4 ± 2.2 μm were observed for BM- and
CB-MSC respectively, Fig. 3.
Discussion
Although equine MSC in suspension are >25 % larger in
diameter than those of other species [8], needle size did
not decrease MSC immediate or delayed viability post-
injection. Aspiration, however, significantly decreased
MSC immediate viability, but did not affect delayed via-
bility. This finding is of significant interest for clinical
administration of equine MSC as care should be taken
in selecting a large diameter needle—such as 18 Ga or
larger—for aspiration of cell suspensions into the syr-
inge. After the syringe is loaded, however, needle selec-
tion can be made without concern for affecting MSC
viability.
We observed significantly higher immediate viability
in MSC injected through 25 Ga needles compared to all
other needles and the no-needle control. The 25 Ga
injections were performed sixth in the series of eight in-
jections, which were then repeated for a second tech-
nical replicate. As such, we do not consider the
experimental setup to have influenced this anomaly.
One potential variable that may be responsible for this
result is that the 25 Ga needle was one of the shortest
needle lengths tested. This may have impacted viability
by shortening the duration of any potential cellular in-
jury as MSC were injected through the needle lumen.
Differences in needle lengths may have affected our re-
sults by varying the duration of injection or aspiration
forces acted on MSC. The needles evaluated however,
are commonly available in veterinary medicine and as
such more likely to be used in everyday use. Considering
there are no clinical implications for increased MSC
viability and that this increase was noticed using the
third-smallest diameter needle evaluated, the increased
viability in this group is not considered clinically
significant.
The injection rate used in this study is likely slower
than the rates used in clinical practice where larger
gauge needles (18–22 Ga) are used. These rates were,
Fig. 2 Viability following aspiration of equine mesenchymal stromal cells; (a) Immediate and (b) delayed viability of equine bone marrow- and
cord blood-derived MSC using a propidium iodide based automated cell counter and resazurin fluorometric assay following aspiration through
various needle diameters. Differences in viability between MSC tissue sources were not detected, as a result data was combined for analysis. Error
bars represent 95 % confidence interval. Asterisks* (*p < 0.05, **p < 0.01, ***p < 0.001) indicate significant difference from non-aspirated samples
Fig. 3 Relative diameter of equine MSC compared to the needles evaluated
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however, the maximum that could be achieved using
small diameter needles (<25 Ga). Significant manual
force was required to achieve the desired injection rate
with a 25 Ga and 27 Ga needle and the rate of 0.25 mL/s
could not be achieved using a 30 Ga needle despite
maximal force (to the extent of bending the syringe
plunger). The use of progressively smaller needles com-
pensated for the relatively slow injection rate used and
allows us to conclude that the forces achieved by MSC
injection using a 3 mL syringe are not sufficient to de-
crease MSC viability or proliferative ability. As smaller
syringes were not evaluated, no inference can be made
about any potential damage that injection through these
syringes may induce on equine MSC. It is possible that a
syringe with a smaller plunger may be able to create suffi-
cient pressure and shear forces on MSC during injection to
decrease immediate or delayed MSC viability. Garvican
et al. [12] recently reported equine BM-MSC injected using
a 2 mL syringe show increased propidium iodide and
annexin V staining (necrosis and apoptosis, respectively)
immediately following injection through 21 or 23 Ga
needles. Differences in methodology are likely responsible
for the differences observed as higher pressures, longer
needles, increased injection rates, and cellular trauma asso-
ciated with negative pressure (aspiration through the test
needle) [9] may have influenced their results. Conflicting
results have been reported as to the effect of injection
through various needle diameters using human and rat
MSC. The most dramatic decreases in MSC viability, in-
creases in markers of apoptosis, and decreased MSC prolif-
eration were observed using MSC concentrations as high
as 5x107/mL, rapid injection rates, small diameter needles
and storage for more than 2 h at room temperature prior
to injection [17].
In previous studies aspiration through the test needle
prior to injection [12, 17, 18] or repeated aspiration and
injection [11] likely also have a negative effect on MSC
viability due to intermittent negative pressure which has
been associated with apoptosis in other studies [9]. Con-
sistent with the observation of detrimental effects on
MSC viability in other species, immediate injection with-
out aspiration of dilute cell suspensions at slow rates re-
sulted in no change in MSC viability or apoptotic
fraction using needles as small as 30 Ga [8, 13]. While
performing the injection studies, we observed that pre-
injection MSC viability had decreased by approximately
10 % towards the end of data collection. We attributed
this to the time that MSC suspensions had been kept at
room temperature (~12 h) and, therefore, elected to de-
crease the number of needles and cell suspensions evalu-
ated for subsequent aspiration studies to reduce the time
MSC were at room temperature. We considered this a
reasonable strategy since in a clinical situation the nee-
dle used to aspirate a cell suspension is routinely
changed prior to injection. We conclude that evaluation
of 18 Ga needles should have been included in the aspir-
ation study due to the significant decrease in viability in
all needles tested. However, although statistical signifi-
cance was detected between MSC aspirated through
20 Ga needles (p = 0.04) and MSC aspirated without a
needle, immediate viability only decreased by 0.6 % on
average from 97.6 to 97.0 %. This is most likely not of
clinical significance, and viability remained well above
the 70 % cut-off suggested by FDA.
Our methodology assessed immediate viability by pro-
pidium iodide exclusion by the intact cellular membrane
and delayed viability through metabolism of the dye
resazurin. Both of these measurements provide informa-
tion as to the viability and physiological state of the un-
differentiated MSC, but do not assess differential
potency or immunomodulatory properties of the MSC.
We do not expect these functional properties of the
MSC to be affected, but future work could determine if
aspiration or injection affects the ability of the MSC to
differentiate into adipogenic, osteogenic or chondrogenic
cell fates or their lymphocyte suppressive properties
in vitro.
This study is limited in that the methods employed
only evaluated membrane integrity and gross metabolic
activity. More sensitive methods of evaluating individual
cell metabolic activity or other measures of cellular
health, such as markers of apoptosis, may have detected
additional differences. Although the needles evaluated
were lengths commonly available in veterinary medicine
different gauge needles were not all uniform in length.
As such the duration of any adverse forces varied be-
tween the various test needles. This could have been
avoided by utilizing needles of a standardized length,
possibly at the expense of clinical utility.
Conclusion
Care should be taken to use large diameter needles when
aspirating equine MSC. However, for injection, needle
selection should be based on clinical experience, know-
ledge of patient behavior, and the anatomical relation-
ship of the targeted structure without concern over
MSC viability.
Ethics approval
This study was specifically approved by the University of
Guelph Animal Care Committee with regard to the col-
lection of equine CB (animal use protocol 1570). Add-
itional research conducted using specimens of this kind
does not require review by the Animal Care Committee
(falls under CCAC Category of Invasiveness A) and
therefore this study can be considered to have been con-
ducted in accordance with institutional ethics guidelines.
No animals were sacrificed during the study. Equine
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umbilical cord blood was collected on two privately
owned commercial farms in Southern Ontario. Four of
five samples were collected on one farm from
Thoroughbred foals. One sample was collected on an-
other farm from a Warmblood foal. Informed consent
was obtained in writing from the horse owners/agents
prior to sampling. The broodmares on the foaling farms
are housed in large foaling boxes. Both farms are staffed
24/7 and mares are under constant video surveillance
and carrying foaling alarms to allow for observed foaling
and assisted delivery if needed. Umbilical cord blood
was collected by the farm staff after receiving instruction
by Dr. Koch. Instruction included video-review of cord
blood collection. Cord blood was collected from an iso-
lated segment of the umbilical cord after the umbilical
cord had been clamped and detached from the foal.
Three of five BM samples were collected immediately
following euthanasia from animals euthanized for rea-
sons unrelated to this study. The remaining two BM-
MSC cell cultures were obtained from excess cultured
BM-MSC of client owned horses. In this instance, ani-
mal owners signed consent forms acknowledging BM-
MSC in excess to the numbers agreed upon would be
donated for research purposes. Since the methods used
for acquisition of BM samples did not require review by
the Animal Care Committee (falls under CCAC Cat-
egory of Invasiveness A), this study has been conducted
in accordance with institutional ethical guidelines.
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